亚洲免费在线观看_亚洲无码国产精品_亚洲蜜桃精久久久久久久久久久久_欧美性猛交XXXXX水多

掃碼關(guān)注公眾號(hào)           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  關(guān)于我們  聯(lián)系我們
91嫖妓站街埯店老熟女,亚洲天堂无码在线播放
Recombinant SARS-Cov-2 Papain-Like Protease, His (bs-41432P)  
訂購(gòu)熱線:400-901-9800
訂購(gòu)郵箱:sales@bioss.com.cn
訂購(gòu)QQ:  400-901-9800
技術(shù)支持:techsupport@bioss.com.cn
100ug/4880.00元
500ug/15800.00元
大包裝/詢價(jià)
產(chǎn)品編號(hào) bs-41432P
英文名稱 Recombinant SARS-Cov-2 Papain-Like Protease, His
中文名稱 重組SARS-CoV-2 (2019-nCoV) Papain-Like Protease
別    名 Papain-like Protease; PLpro; PL-PRO; pp1a; Replicase polyprotein 1a; Recombinant SARS-Cov-2 Papain-Like Protease, His  新冠病毒PLpro; 新冠PLpro; SARS-CoV-2 PLpro;
理論分子量 35.8 kDa
檢測(cè)分子量 26
性    狀 Liquid
濃    度 >0.5 mg/ml
物    種 SARS-Cov-2
序    列 1564-1880/7096
純    度 >90% as determined by SDS-PAGE
純化方法 AC
內(nèi)毒素 Not analyzed
表達(dá)系統(tǒng) E.coli
活性 Not tested
標(biāo)簽 His
保存條件 Stored at -70℃ or -20℃. Avoid repeated freeze/thaw cycles.
注意事項(xiàng) This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV. PLpro is a cysteine protease located within the non-structural protein 3 (NS3) section of the viral polypeptide. PLPro activity is required to process the viral polyprotein into functional, mature subunits; specifically, PLPro cleaves a site at the amino-terminus of the viral replicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and deISGylating activity. In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons.

版權(quán)所有 2004-2026 cqshengou.com 北京博奧森生物技術(shù)有限公司
通過國(guó)際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號(hào): 00124Q34771R2M/1100
通過國(guó)際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號(hào): CQC24QY10047R0M/1100
京ICP備05066980號(hào)-1         京公網(wǎng)安備110107000727號(hào)